Your browser doesn't support javascript.
loading
Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
Qu, Changbo; Fuhler, Gwenny M; Pan, Yihang.
Afiliação
  • Qu C; Tomas Lindahl Nobel Laureate Laboratory, Precision Medicine Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
  • Fuhler GM; Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.
  • Pan Y; Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 3015 CN Rotterdam, The Netherlands.
Int J Mol Sci ; 22(11)2021 May 26.
Article em En | MEDLINE | ID: mdl-34073529
ABSTRACT
COVID-19 has rapidly become a pandemic worldwide, causing extensive and long-term health issues. There is an urgent need to identify therapies that limit SARS-CoV-2 infection and improve the outcome of COVID-19 patients. Unbalanced lung inflammation is a common feature in severe COVID-19 patients; therefore, reducing lung inflammation can undoubtedly benefit the clinical manifestations. Histamine H1 receptor (H1 receptor) antagonists are widely prescribed medications to treat allergic diseases, while recently it has emerged that they show significant promise as anti-SARS-CoV-2 agents. Here, we briefly summarize the novel use of H1 receptor antagonists in combating SARS-CoV-2 infection. We also describe the potential antiviral mechanisms of H1 receptor antagonists on SARS-CoV-2. Finally, the opportunities and challenges of the use of H1 receptor antagonists in managing COVID-19 are discussed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / NF-kappa B / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 / Antagonistas dos Receptores Histamínicos H1 / Anti-Inflamatórios Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / NF-kappa B / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 / Antagonistas dos Receptores Histamínicos H1 / Anti-Inflamatórios Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China